A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5.


Journal

BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552

Informations de publication

Date de publication:
11 05 2020
Historique:
received: 11 11 2019
accepted: 29 04 2020
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 17 7 2020
Statut: epublish

Résumé

Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature death. CLN5 was initially named Finnish variant late infantile NCL, it is now known to be present in other ethnic populations and with variable age of onset. Few CLN5 patients had been reported in Chinese population. In this paper, we report the symptoms of a Chinese patient who suffer from developmental regression and grand mal epilepsy for several years. The DNA was extracted from peripheral blood of proband and both parents, and then whole exome sequencing was performed using genomic DNA. Both sequence variants and copy number variants (CNVs) were analyzed and classified according to guidelines. As the result, a novel frameshift mutation c.718_719delAT/p.Met240fs in CLN5 and a de novo large deletion at 13q21.33-q31.1 which unmasked the frameshift mutation were identified in the proband. Despite the large de novo deletion, which can be classified as a pathogenic copy number variant (CNV), the patient's clinical presentation is mostly consistent with that of CLN5, except for early developmental delay which is believed due to the large deletion. Both variants were detected simultaneously by exome sequencing. This is the first report of whole gene deletion in combination with a novel pathogenic sequence variant in a CLN5 patient. The two mutations detected with whole exome sequencing simultaneously proved the advantage of the sequencing technology for genetic diagnostics.

Sections du résumé

BACKGROUND
Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature death. CLN5 was initially named Finnish variant late infantile NCL, it is now known to be present in other ethnic populations and with variable age of onset. Few CLN5 patients had been reported in Chinese population.
CASE PRESENTATION
In this paper, we report the symptoms of a Chinese patient who suffer from developmental regression and grand mal epilepsy for several years. The DNA was extracted from peripheral blood of proband and both parents, and then whole exome sequencing was performed using genomic DNA. Both sequence variants and copy number variants (CNVs) were analyzed and classified according to guidelines. As the result, a novel frameshift mutation c.718_719delAT/p.Met240fs in CLN5 and a de novo large deletion at 13q21.33-q31.1 which unmasked the frameshift mutation were identified in the proband. Despite the large de novo deletion, which can be classified as a pathogenic copy number variant (CNV), the patient's clinical presentation is mostly consistent with that of CLN5, except for early developmental delay which is believed due to the large deletion. Both variants were detected simultaneously by exome sequencing.
CONCLUSIONS
This is the first report of whole gene deletion in combination with a novel pathogenic sequence variant in a CLN5 patient. The two mutations detected with whole exome sequencing simultaneously proved the advantage of the sequencing technology for genetic diagnostics.

Identifiants

pubmed: 32393339
doi: 10.1186/s12881-020-01039-5
pii: 10.1186/s12881-020-01039-5
pmc: PMC7216669
doi:

Substances chimiques

CLN5 protein, human 0
Lysosomal Membrane Proteins 0
Membrane Proteins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100

Subventions

Organisme : National key research and development program
ID : 2018YFC1002501
Pays : International
Organisme : the Major Research Plan of the Provincial Science and Technology Foundation of Guangxi
ID : Grant No.AB16380214
Pays : International
Organisme : "YUMIAOJIHUA" Project of The Maternal & Child Health Hospital of Guangxi Zhuang Autonomous Region
ID : GXWCH-YMJH-2017005
Pays : International

Références

Dev Med Child Neurol. 2017 Aug;59(8):777-778
pubmed: 28556060
Neurogenetics. 2005 Sep;6(3):107-26
pubmed: 15965709
Zhonghua Yi Xue Za Zhi. 2016 Nov 22;96(43):3504-3507
pubmed: 27903347
Neurology. 2010 Feb 16;74(7):565-71
pubmed: 20157158
Prenat Diagn. 1998 Nov;18(11):1169-73
pubmed: 9854727
Neurology. 2005 Feb 22;64(4):740-2
pubmed: 15728307
Neurology. 2000 Aug 22;55(4):579-81
pubmed: 10953198
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Brain Dev. 2016 Aug;38(7):674-7
pubmed: 26846731
Biochim Biophys Acta. 2013 Nov;1832(11):1827-30
pubmed: 23542453
Mol Genet Metab. 2006 Nov;89(3):245-53
pubmed: 16814585
Rev Neurol. 2012 May 1;54(9):544-50
pubmed: 22532218
Neuropediatrics. 1982 Aug;13(3):135-41
pubmed: 7133332
Hum Mutat. 2009 May;30(5):E651-61
pubmed: 19309691
Nat Genet. 1998 Jul;19(3):286-8
pubmed: 9662406
Neuropediatrics. 1991 May;22(2):92-6
pubmed: 1649978
Biochim Biophys Acta. 2015 Oct;1852(10 Pt B):2237-41
pubmed: 26026925
Electrophoresis. 2012 Dec;33(24):3798-809
pubmed: 23160995
Dev Med Child Neurol. 2017 Aug;59(8):815-821
pubmed: 28542837
J Neurol. 2015 Jan;262(1):173-8
pubmed: 25359263
J Child Neurol. 2011 May;26(5):625-9
pubmed: 21447811
Clin Genet. 2008 Sep;74(3):213-22
pubmed: 18684116
Hum Mol Genet. 2017 May 1;26(9):1678
pubmed: 28334871

Auteurs

Wei Li (W)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Xin Fan (X)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Yue Zhang (Y)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Limei Huang (L)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Tingting Jiang (T)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Zailong Qin (Z)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Jiasun Su (J)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Jingrong Luo (J)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Shang Yi (S)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.

Shujie Zhang (S)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.

Yiping Shen (Y)

Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China. yiping.shen@childrens.harvard.edu.
Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. yiping.shen@childrens.harvard.edu.
Division of Genetics and Genomics, Boston Children's Hospital, Boston, USA. yiping.shen@childrens.harvard.edu.
Department of Neurology, Harvard Medical School, Boston, MA, 02115, USA. yiping.shen@childrens.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH